TherapeuticsMD Inc (NASDAQ:TXMD)‘s stock had its “buy” rating reissued by analysts at Jefferies Group LLC in a report issued on Friday. They currently have a $15.00 price objective on the stock. Jefferies Group LLC’s price objective indicates a potential upside of 126.93% from the company’s current price.

Other research analysts have also issued reports about the company. Oppenheimer Holdings Inc. set a $10.00 target price on TherapeuticsMD and gave the company a “buy” rating in a report on Thursday, August 17th. Morgan Stanley began coverage on TherapeuticsMD in a report on Friday. They issued an “equal weight” rating and a $6.00 target price for the company. Deutsche Bank AG began coverage on TherapeuticsMD in a report on Friday, July 21st. They issued a “buy” rating and a $10.00 target price for the company. Cowen and Company reiterated an “outperform” rating and issued a $13.00 target price on shares of TherapeuticsMD in a report on Monday, July 17th. Finally, Zacks Investment Research upgraded TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. TherapeuticsMD has an average rating of “Buy” and an average target price of $14.88.

TherapeuticsMD (TXMD) traded down 4.34% on Friday, hitting $6.61. The stock had a trading volume of 2,397,542 shares. The company’s market cap is $1.35 billion. The firm’s 50-day moving average is $5.83 and its 200-day moving average is $5.56. TherapeuticsMD has a 52-week low of $3.50 and a 52-week high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Thursday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.01. The firm had revenue of $4.25 million during the quarter, compared to analyst estimates of $4.91 million. TherapeuticsMD had a negative return on equity of 77.41% and a negative net margin of 462.94%. TherapeuticsMD’s revenue was down 3.4% compared to the same quarter last year. During the same period last year, the business posted ($0.11) earnings per share. Equities research analysts anticipate that TherapeuticsMD will post ($0.44) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/08/therapeuticsmd-inc-txmd-given-buy-rating-at-jefferies-group-llc.html.

In other TherapeuticsMD news, Director Tommy G. Thompson purchased 5,000 shares of the firm’s stock in a transaction on Wednesday, August 30th. The stock was bought at an average cost of $5.99 per share, with a total value of $29,950.00. Following the acquisition, the director now directly owns 3,555 shares of the company’s stock, valued at $21,294.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Managed Account Services Inc. lifted its holdings in TherapeuticsMD by 5.5% during the 2nd quarter. Managed Account Services Inc. now owns 19,103 shares of the company’s stock worth $101,000 after buying an additional 1,000 shares during the last quarter. Amalgamated Bank lifted its holdings in TherapeuticsMD by 7.2% during the 2nd quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock worth $104,000 after buying an additional 1,322 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in TherapeuticsMD by 3.9% during the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock worth $114,000 after buying an additional 818 shares during the last quarter. Traynor Capital Management Inc. lifted its holdings in TherapeuticsMD by 14.0% during the 2nd quarter. Traynor Capital Management Inc. now owns 22,799 shares of the company’s stock worth $123,000 after buying an additional 2,799 shares during the last quarter. Finally, Greenwood Capital Associates LLC lifted its holdings in TherapeuticsMD by 17.5% during the 1st quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock worth $146,000 after buying an additional 3,022 shares during the last quarter.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Analyst Recommendations for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.